Compare Pfizer Inc (PFE) vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF (VTIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF — how do they compare? Pfizer Inc trades at $27.81 (market cap $158.56B), while Vanguard Sht-Term Inflation-Protected Sec Idx ETF trades at $49.45 (market cap $73.20B). The key difference: Pfizer Inc is far larger — about 2.2× Vanguard Sht-Term Inflation-Protected Sec Idx ETF's market cap, and Pfizer Inc pays a 6.18% dividend while Vanguard Sht-Term Inflation-Protected Sec Idx ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and Vanguard Sht-Term Inflation-Protected Sec Idx ETF for 91 Days on average.
| PFE | VTIP | |
|---|---|---|
Market Cap | $158.56B | $73.20B |
Volume | 44,138,282 | 2,511,360 |
Sector | Health | — |
52-Week High | $29.02 | $50.46 |
52-Week Low | $23.67 | $48.38 |
Typical Hold Time | 158 Days | 91 Days |
Enterprise Value | $210.06B | — |
Dividend Yield | 6.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
VTIP (Vanguard Short-Term Inflation-Protected Securities ETF) trades at $48.46, showing minimal daily movement with a 0.08% gain. Technical indicators present mixed signals with a bearish overall trend but bullish oscillators. The ETF focuses on short-duration TIPS to hedge inflation while minimizing interest rate sensitivity. Recent institutional buying activity includes NewEdge Advisors increasing their position by 45.5% in Q2 2026.
The ETF offers defensive positioning amid persistent inflation above the Fed's 2% target for 65 consecutive months. While providing inflation protection with reduced duration risk, VTIP faces headwinds from potential Fed policy shifts and competition from other TIPS vehicles. Real yields at multi-decade highs create attractive entry points for inflation-sensitive allocations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Vanguard Sht-Term Inflation-Protected Sec Idx ETF
The index is a market-capitalization-weighted index that includes all inflation-protected public obligations issued by the US Treasury with remaining maturities of less than 5 years. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the securities that make up the index, holding each security in approximately the same proportion as its weighting in the index.
Read more on VTIP →
